<DOC>
	<DOCNO>NCT00000829</DOCNO>
	<brief_summary>To assess whether HIV-infected infant receive heptavalent pneumococcal conjugate vaccine local reaction site injection systemic reaction placebo subject . To assess whether vaccine immunogenic placebo follow third vaccination . Children HIV infection increase risk invasive pneumococcal infection , particularly bacteremia . A large proportion pneumococcal disease cause limited number serotypes . The maximum number pneumococcal serotypes include new conjugate vaccine felt limited amount carrier protein . A heptavalent pneumococcal conjugate vaccine develop consist pneumococcal capsular saccharide serotypes 4 , 6B , 9V , 14 , 18C , 19F , 23F bound diphtheria toxin mutant carrier protein .</brief_summary>
	<brief_title>A Double-Blind Placebo-Controlled Trial Safety Immunogenicity Seven Valent Pneumococcal Conjugate Vaccine Presumed HIV-Infected Infants</brief_title>
	<detailed_description>Children HIV infection increase risk invasive pneumococcal infection , particularly bacteremia . A large proportion pneumococcal disease cause limited number serotypes . The maximum number pneumococcal serotypes include new conjugate vaccine felt limited amount carrier protein . A heptavalent pneumococcal conjugate vaccine develop consist pneumococcal capsular saccharide serotypes 4 , 6B , 9V , 14 , 18C , 19F , 23F bound diphtheria toxin mutant carrier protein . Infants randomize receive either heptavalent pneumococcal conjugate vaccine placebo intramuscular injection study month 0 , 2 , 4 , 15 month age . Additionally , patient receive PNU-IMUNE 23 ( pneumococcal polyvalent vaccine ) 24 month age .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antipyretics rectal temperature &gt; = 100.4 F. Antiretroviral therapy . Patients must : HIV positivity . Birth weight least 1800 g ( 3.75 lb ) . Consent compliance parent guardian . NOTE : Coenrollment therapeutic protocol ( except ACTG 218 , 230 , 279 ) permit . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Enrollment HIV vaccine trial . Major congenital anomaly incapacitate , result immunologic abnormality , require major surgical procedure . Congenital immunoglobulin deficiency , SS SC hemoglobinopathy , asplenia . Hypogammaglobulinemia . Concurrent Medication : Excluded : Prophylactic antipyretic . Patients follow prior condition exclude : Acute moderate severe intercurrent illness fever within 72 hour prior study entry . Prior Medication : Excluded : Any prior pneumococcal vaccine . Measles vaccine within 1 month prior study vaccination . Any routine vaccine within 1 week prior study vaccination . Any immunosuppressant agent , include prednisone , 6 week . Prior Treatment : Excluded : Blood product within 56 day prior study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Pneumococcal Infections</keyword>
	<keyword>Bacterial Vaccines</keyword>
</DOC>